Literature DB >> 22299133

Botulinum toxin for the lower urinary tract.

Yao-Chi Chuang1, Hann-Chorng Kuo, Michael B Chancellor.   

Abstract

Botulinum toxins (BoNTs) are known for their ability to potently and selectively modulate neurotransmission for successful long-term treatment of muscle hypercontractility. Recent studies suggest that BoNT has effects on modulation of sensory processing, inflammation and glandular function. Urologists and urogynaecologists have become interested in the potential application of BoNTs in patients with lower urinary tract symptoms, including detrusor and sphincter overactivity, bladder hypersensitivity, interstitial cystitis/painful bladder symptoms and benign prostatic hyperplasia. We review the biological action of BoNT in bladder and prostate, and present the techniques and results of the clinical studies with BoNT in the lower urinary tract.
© 2010 THE AUTHORS. JOURNAL COMPILATION © 2010 BJU INTERNATIONAL.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 22299133     DOI: 10.1111/j.1464-410x.2010.09317.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  9 in total

Review 1.  Single compartment drug delivery.

Authors:  Michael J Cima; Heejin Lee; Karen Daniel; Laura M Tanenbaum; Aikaterini Mantzavinou; Kevin C Spencer; Qunya Ong; Jay C Sy; John Santini; Carl M Schoellhammer; Daniel Blankschtein; Robert S Langer
Journal:  J Control Release       Date:  2014-05-04       Impact factor: 9.776

2.  Intradetrusor injection of botulinum toxin A in children: a 10-year single centre experience.

Authors:  Riyad Peeraully; Christine Lam; Nikita Mediratta; Ramnik Patel; Alun Williams; Manoj Shenoy; Nia Fraser
Journal:  Int Urol Nephrol       Date:  2019-06-10       Impact factor: 2.370

Review 3.  Efficacy and safety of botulinum toxin injection for interstitial cystitis/bladder pain syndrome: a systematic review and meta-analysis.

Authors:  Sung Ryul Shim; Young Joo Cho; In-Soo Shin; Jae Heon Kim
Journal:  Int Urol Nephrol       Date:  2016-04-30       Impact factor: 2.370

4.  Non-invasive evaluation of botulinum-A toxin treatment efficacy in children with refractory overactive bladder.

Authors:  Murat Uçar; Ahsen Karagözlü Akgül; Ayşe Parlak; Cem Yücel; Nizamettin Kılıç; Emin Balkan
Journal:  Int Urol Nephrol       Date:  2018-07-02       Impact factor: 2.370

5.  Expression of apoptosis-regulating genes in the rat prostate following botulinum toxin type A injection.

Authors:  Tiago Gorgal; Ana Charrua; João F Silva; António Avelino; Paulo Dinis; Francisco Cruz
Journal:  BMC Urol       Date:  2012-01-04       Impact factor: 2.264

Review 6.  Promise and the Pharmacological Mechanism of Botulinum Toxin A in Chronic Prostatitis Syndrome.

Authors:  Chien-Hsu Chen; Pradeep Tyagi; Yao-Chi Chuang
Journal:  Toxins (Basel)       Date:  2019-10-11       Impact factor: 4.546

Review 7.  Potential Effect of Liposomes and Liposome-Encapsulated Botulinum Toxin and Tacrolimus in the Treatment of Bladder Dysfunction.

Authors:  Joseph J Janicki; Michael B Chancellor; Jonathan Kaufman; Michele A Gruber; David D Chancellor
Journal:  Toxins (Basel)       Date:  2016-03-18       Impact factor: 4.546

8.  Efficacy of botulinum toxin type A 100 Units versus 200 units for treatment of refractory idiopathic overactive bladder.

Authors:  Osama Abdelwahab; Hammouda Sherif; Tark Soliman; Ihab Elbarky; Aly Eshazly
Journal:  Int Braz J Urol       Date:  2015 Nov-Dec       Impact factor: 1.541

Review 9.  Intravesical liposome drug delivery and IC/BPS.

Authors:  Joseph J Janicki; Michele A Gruber; Michael B Chancellor
Journal:  Transl Androl Urol       Date:  2015-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.